Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18636763 | PROCESS FOR PREPARING 6-SUBSTITUTED-1-(2H)-ISOQUINOLINONES AND INTERMEDIATE COMPOUND | April 2024 | July 2024 | Allow | 3 | 2 | 0 | Yes | No |
| 18509667 | METHODS OF TREATING CANCER USING HETEROARYL-BIPHENYL AMIDE DERIVATIVES | November 2023 | January 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18319066 | PYRAZOLE DERIVATIVES | May 2023 | June 2025 | Allow | 25 | 2 | 0 | Yes | No |
| 18132479 | METHOD FOR PREPARING 18F-BPA AND INTERMEDIATE | April 2023 | February 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18188912 | INTERMEDIATE USEFUL FOR THE SYNTHESIS OF TGF-BETA INHIBITORS AND A METHOD OF PREPARING TGF-BETA INHIBITORS USING THE SAME | March 2023 | January 2024 | Allow | 10 | 1 | 0 | No | No |
| 17922619 | Ring Closing Synthesis of Macrocyclic MCL-1 Inhibitor Intermediates | November 2022 | June 2025 | Allow | 31 | 0 | 0 | Yes | No |
| 17965908 | MECHANOCHEMICAL DYNAMIC FOR FOCAL CANCER TREATMENT | October 2022 | September 2024 | Allow | 23 | 2 | 1 | Yes | No |
| 17954686 | METHODS AND COMPOSITIONS RELATING TO STEROID HORMONE RECEPTOR-DEPENDENT PROLIFERATIVE DISORDERS | September 2022 | November 2023 | Allow | 14 | 0 | 0 | No | No |
| 17914565 | BENZIMIDAZOLE THIOPHENE DERIVATIVE COMPOUNDS INDUCING SELECTIVE DEGRADATION OF PLK1 | September 2022 | May 2025 | Allow | 32 | 0 | 0 | Yes | No |
| 17933660 | HETERO-TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | September 2022 | February 2024 | Allow | 26 | 1 | 1 | No | No |
| 17932688 | PROCESS FOR PREPARING TETRALIN COMPOUNDS | September 2022 | June 2024 | Allow | 21 | 1 | 1 | Yes | No |
| 17932218 | ANTI-VIRAL COMPOUNDS | September 2022 | April 2024 | Allow | 19 | 1 | 1 | No | No |
| 17930882 | CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES | September 2022 | March 2025 | Allow | 30 | 1 | 1 | No | No |
| 17300319 | METHOD FOR TREATING PERIPHERAL NERVE SHEATH TUMOR | August 2022 | May 2024 | Allow | 20 | 1 | 1 | No | No |
| 17822450 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS | August 2022 | January 2024 | Allow | 17 | 1 | 0 | No | No |
| 17905127 | HYDRATE OF DIMETHYLAMINOMICHELIOLIDE FUMARATE AND PREPARATION METHOD THEREFOR AND USE THEREOF | August 2022 | March 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 17929002 | PHYSICS-DRIVEN DISCOVERY OF NOVEL SMALL THERAPEUTIC COMPOUNDS FOR USE AS A BCL-2 INHIBITOR | August 2022 | December 2024 | Allow | 28 | 0 | 0 | Yes | No |
| 17760464 | PHYSICS-DRIVEN DISCOVERY OF NOVEL SMALL THERAPEUTIC COMPOUNDS FOR USE AS A BCL-2 INHIBITOR | August 2022 | February 2025 | Allow | 30 | 0 | 0 | Yes | No |
| 17811327 | COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES, CONTAINING DITERPENE-BASED COMPOUND | July 2022 | September 2024 | Allow | 27 | 4 | 0 | Yes | No |
| 17790211 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | June 2022 | May 2025 | Allow | 35 | 0 | 0 | Yes | No |
| 17757437 | MACROCYCLIC COMPOUNDS | June 2022 | April 2025 | Allow | 34 | 0 | 0 | Yes | No |
| 17805006 | COMPLEX SALT OF RUPESTONIC ACID AND ALKALOID, PREPARATION METHOD THEREFOR AND USE THEREOF | June 2022 | January 2024 | Allow | 20 | 1 | 0 | No | No |
| 17824461 | METHOD FOR PREPARING DEUTERATED ORGANIC COMPOUNDS | May 2022 | February 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17746628 | TERPENOL ETHERS | May 2022 | June 2025 | Abandon | 37 | 1 | 1 | No | No |
| 17769402 | PHOTOCHEMICAL PROCESS FOR PRODUCING (4R,4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1,6-NAPHTHYRIDIN-3-CARBOXAMIDE | April 2022 | April 2025 | Allow | 36 | 0 | 0 | Yes | No |
| 17642838 | COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING NEURODEGENERATIVE DISEASES AND/OR A CLINICAL CONDITION THEREOF | March 2022 | March 2025 | Allow | 36 | 0 | 0 | Yes | No |
| 17580884 | NOVEL COMPOUNDS FOR PREPARATION OF MICROTUBULE ASSOCIATED TAU PROTEIN IMAGING AGENTS, PREPARATION METHODS AND MEDICINAL USES THEREOF | January 2022 | March 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17559069 | COMPOUND AND PHOTOELECTRIC DEVICE, IMAGE SENSOR, AND ELECTRONIC DEVICE INCLUDING THE SAME | December 2021 | March 2025 | Allow | 39 | 2 | 1 | Yes | No |
| 17615718 | NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | December 2021 | September 2024 | Allow | 33 | 0 | 0 | Yes | No |
| 17614086 | MICROBIOCIDAL DERIVATIVES | November 2021 | June 2025 | Allow | 43 | 1 | 1 | No | No |
| 17610112 | BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | November 2021 | April 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17482996 | (--)-Huperzine A Processes and Related Compositions and Methods of Treatment | September 2021 | July 2024 | Allow | 34 | 0 | 0 | Yes | No |
| 17431837 | MINOCYCLINE FOR THE TREATMENT OF PITT-HOPKINS SYNDROME | August 2021 | September 2024 | Allow | 37 | 0 | 0 | No | No |
| 17431224 | PESTICIDALLY ACTIVE AZOLE-AMIDE COMPOUNDS | August 2021 | March 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17429427 | Hemiasterlin Derivative and Antibody-Drug Conjugate Thereof | August 2021 | August 2024 | Allow | 36 | 0 | 0 | No | No |
| 17427501 | USE OF COMPOSITION CONTAINING CDK4/6 INHIBITOR IN COMBINATION WITH ANASTROZOLE IN PREPARATION OF MEDICAMENT FOR TREATING TUMOR DISEASES | July 2021 | January 2025 | Abandon | 41 | 1 | 0 | No | No |
| 17423218 | COMPOSITIONS AND METHODS FOR TREATING DIABETES | July 2021 | December 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17422535 | CHEMICALLY AND PHYSICALLY STABLE TOPICAL OPHTHALMIC NEPAFENAC-BASED FORMULATIONS | July 2021 | June 2025 | Allow | 47 | 2 | 0 | Yes | No |
| 17422308 | OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS | July 2021 | March 2025 | Allow | 44 | 2 | 1 | Yes | No |
| 17370697 | REDUCTIVE DIMERIZATION OF FURFURAL VIA A CONTINUOUS PROCESS | July 2021 | January 2024 | Allow | 30 | 2 | 1 | Yes | No |
| 17418439 | EICOSAPENTAENOIC ACID ALKYL ESTER-CONTAINING COMPOSITION AND METHOD FOR PRODUCING SAME | June 2021 | January 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17354003 | METHODS OF TREATING CANCER USING HETEROARYL-BIPHENYL AMIDE DERIVATIVES | June 2021 | March 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17414797 | COMPOUNDS FOR TREATING LYMPHOMA OR A T-CELL MALIGNANT DISEASE | June 2021 | April 2025 | Allow | 46 | 2 | 0 | Yes | No |
| 17414095 | Compounds for the Reduction of the Deleterious Activity of Extended Nucleotide Repeat Containing Genes | June 2021 | January 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17346597 | SOLID STATE FORMS OF IXAZOMIB CITRATE | June 2021 | December 2024 | Allow | 42 | 1 | 0 | No | No |
| 17413473 | HETEROCYCLIC COMPOUND | June 2021 | May 2024 | Allow | 35 | 0 | 0 | Yes | No |
| 17311431 | PROCESS ROUTE OF COMPOUND OF FORMULA (IV), CRYSTAL FORM AND PREPARATION METHOD THEREFOR | June 2021 | May 2024 | Allow | 35 | 0 | 0 | No | No |
| 17331036 | COMPOSITION FOR PREVENTING OR TREATING CARDIOFACIOCUTANEOUS SYNDROME | May 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17329079 | 5-HYDROXYTRYPTAMINE 1B RECEPTOR-STIMULATING AGENT FOR ENHANCING IN VIVO ENGRAFTMENT POTENTIAL | May 2021 | October 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17291707 | NOVEL COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | May 2021 | September 2024 | Allow | 40 | 1 | 0 | No | No |
| 17306273 | COMPOSITION AND METHOD FOR TREATING FUNGAL SKIN CONDITIONS AND INFLAMMATION | May 2021 | May 2024 | Allow | 37 | 0 | 0 | Yes | No |
| 17245691 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS | April 2021 | June 2025 | Abandon | 50 | 1 | 1 | No | No |
| 17290240 | SOLID FORMS OF 2-METHYL-1-[(4-[6-(TRIFLUOROMETHYL) PYRIDIN-2-YL]-6-{[2-(TRIFLUOROMETHYL)PYRIDIN-4-YL]AMINO}-1,3,5-TRIAZIN-2-YL) AMINO]PROPAN-2-OL | April 2021 | September 2024 | Allow | 41 | 2 | 0 | No | No |
| 17289516 | METHODS FOR ADMINISTERING CORTICOSTEROIDS | April 2021 | November 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17289476 | AMINOPYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | April 2021 | September 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17289269 | AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CONDITIONS RELATED TO THE MODULATION OF IL-12, IL-23 AND/OR IFN-ALPHA | April 2021 | October 2024 | Allow | 41 | 2 | 1 | No | No |
| 17288397 | ANTIBACTERIAL AGENT AGAINST ENTEROBACTERIUM WHICH CONTAINS EQUOL AS ACTIVE INGREDIENT | April 2021 | April 2025 | Abandon | 48 | 2 | 0 | No | No |
| 17287322 | CRYSTAL FORM OF MALEATE OF TYROSINE KINASE INHIBITOR AND PREPARATION METHOD THEREFOR | April 2021 | July 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17287489 | METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM PRE-OPERATIVELY AND IN COMBINATION WITH OTHER DRUGS | April 2021 | November 2024 | Abandon | 42 | 1 | 0 | No | No |
| 17286620 | Formulations of Antiviral Compounds | April 2021 | November 2024 | Abandon | 43 | 2 | 0 | No | No |
| 17280371 | BALIPODECT FOR TREATING OR PREVENTING AUTISM SPECTRUM DISORDERS | March 2021 | March 2025 | Allow | 47 | 2 | 0 | No | No |
| 17278429 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | March 2021 | February 2024 | Allow | 35 | 1 | 0 | No | No |
| 17277535 | INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION | March 2021 | November 2024 | Allow | 44 | 1 | 0 | Yes | No |
| 17202195 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | March 2021 | July 2024 | Allow | 60 | 2 | 0 | No | No |
| 17275158 | PYRIDOPYRAZINE AND PYRIDOTRIAZINE INHIBITORS OF INFLUENZA VIRUS REPLICATION | March 2021 | November 2023 | Allow | 32 | 0 | 0 | No | No |
| 17274990 | FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | March 2021 | November 2023 | Allow | 32 | 0 | 0 | No | No |
| 17273726 | SELECTIVE ANDROGEN RECEPTOR DEGRADER (SARD) LIGANDS AND METHODS OF USE THEREOF | March 2021 | July 2024 | Allow | 40 | 2 | 0 | No | No |
| 17191205 | THERAPEUTIC COMBINATIONS COMPRISING A C-RAF INHIBITOR | March 2021 | February 2024 | Allow | 36 | 1 | 0 | No | No |
| 17270384 | A NEW ZINC COMPLEX, PREPARATION THEREOF AND USE THEREOF FOR TRERAPY OF HUMAN AND ANIMAL DISEASES | February 2021 | April 2024 | Allow | 38 | 1 | 0 | No | No |
| 17268780 | LIQUID BENDAMUSTINE PHARMACEUTICAL COMPOSITIONS | February 2021 | May 2024 | Allow | 39 | 1 | 0 | No | No |
| 17151586 | VITAMIN SUPPLEMENT COMPOSITIONS FOR INJECTION | January 2021 | September 2023 | Allow | 32 | 0 | 0 | No | No |
| 17258013 | CO-CRYSTAL OF SORAFENIB DERIVATIVES AND PROCESS FOR PREPARATION THEREOF | January 2021 | February 2024 | Allow | 37 | 1 | 0 | No | No |
| 17107669 | FERROELECTRIC FLUORESCENT SELF-ASSEMBLY COMPOUND AND ORGANIC ELECTRONIC ELEMENT INCLUDING THE SAME | November 2020 | April 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 17096001 | Longer-Lived Ruthenium Olefin Metathesis Catalysts Supported by Hemi-Labile Carbene Ligands | November 2020 | October 2024 | Allow | 47 | 3 | 1 | Yes | No |
| 17052224 | NOVEL SULFONAMIDE DERIVATIVES HAVING SELECTIVE NOX INHIBITING ACTIVITY | November 2020 | September 2024 | Allow | 46 | 2 | 1 | Yes | No |
| 16959906 | PANDA AS NOVEL THERAPEUTIC | July 2020 | July 2024 | Abandon | 49 | 0 | 1 | No | No |
| 16755056 | Organic Electronic Device Comprising an Organic Semiconductor Layer | April 2020 | April 2025 | Abandon | 60 | 6 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner CHICKS, ASHLI ARIANA works in Art Unit 1626 and has examined 76 patent applications in our dataset. With an allowance rate of 73.7%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 37 months.
Examiner CHICKS, ASHLI ARIANA's allowance rate of 73.7% places them in the 30% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by CHICKS, ASHLI ARIANA receive 1.01 office actions before reaching final disposition. This places the examiner in the 13% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by CHICKS, ASHLI ARIANA is 37 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +42.6% benefit to allowance rate for applications examined by CHICKS, ASHLI ARIANA. This interview benefit is in the 91% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 38.9% of applications are subsequently allowed. This success rate is in the 87% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 64.7% of cases where such amendments are filed. This entry rate is in the 86% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.